Kinase‐Deficient CMVpp65 Triggers a CMVpp65 Specific T‐Cell Immune Response in HLA‐A*0201.Kb Transgenic Mice after DNA Immunization
Year: 2002
Type: article
Abstract: CMVpp65, a candidate component of human cytomegalovirus (CMV) vaccines, has phosphokinase (PK) activity that could affect vaccine safety. A mutated form of CMVpp65 substituting asparagine for lysine at the adenosine triphosphate (ATP)-binding site (CMVpp65mII) is kinase-deficient. Using DNA immunizations in a transgenic human leucocyte antigen (HLA)A*0201.Kb mouse model, the mutated CMVpp65 induced cytotoxic T lymphocytes (CTL) immunity similarly to native CMVpp65. Murine CTL lines generated from these immunizations killed human cells either after sensitization with CMVpp65-specific peptides or after infection with either CMV-Towne strain or rvac-pp65. It is proposed that CMVpp65mII be evaluated in candidate vaccines for CMV.
Authors: G. Gallez‐Hawkins, N. A. Lomeli, X. L. Li, Z. Q. Yao, C. La Rosa, D. J. Diamond, J. A. Zaia
Institutions: Beckman Research Institute, University of Virginia
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: LIPOPEPTIDE VACCINE AGAINST CONSERVED TARGETS OF HIV, VACCINATION FOR CMV IN AIDS PATIENTS UNDERGOING HAART, Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine, G2855000504, G3975501210, Hematopoietic Cell Transplantation for Hematologic Malignancies, G7195877558, G7357366808, G7744060850, G9000308534
OpenAlex ID: W2009625616